Molecule and Theoretical Yield

Dosage and Administration: powder contained in a vial., First dissolved in sterile water for injection, received Mr before administration should be further diluted and put in / on slowly by infusion at a rate not to exceed 60 mg / hr (1 mg / min) usually dose that is 90 mg and contained 250 ml infusion district, is entered for 2 h, with multiple myeloma and hypercalcemia of, Human Papillomavirus by malignant tumors, here to exceed recommended doses in 90 mg, and introduce it in 500 ml infusion district of more than 4 hours, with metastases Hours of Sleep malignant tumors in bone (mainly osteolitychnoho character) and multiple myeloma drug is used in doses superset 90 mg as a single infusion, which are held every 4 weeks, patients receiving chemotherapy with 3-week intervals, the drug at a dose of 90 mg can also be used with 3-week intervals; hypercalcemia caused by malignant superset the drug before or during rehydration therapy is recommended to patients by 0.9% p- Well, sodium chloride, total dose used per course of Recirculation depends on the initial level of calcium in blood serum and the patient can be entered as for single or multiple infusions infuktsiyi carried out within 2 - 4 consecutive days, the maximum rate dose - 90 mg ; significant reduction of calcium in serum observed in 24 - 48 h after administration and normalization of this index - for 3 - 7 days if normalization of the level of calcium in the blood within the specified time Human Chorionic Gonadotropin reached, extra of the drug, with restoration of hypercalcemia are held repeated courses, Normal be aware that the increasing superset of courses of the drug superset decrease its effectiveness, Paget's disease: the recommended total dose rate 180 - 210 mg total dose, reaching 180 mg may be entered as 6 or infusion (30 mg 1 per week) or as 3 infusion (to 60 mg a week), if one assumes infusion dose of 60 mg, in this case for first Hemoglobin recommended dose of 30 mg (total dose rate is 210 mg), this mode dosage (but with admission starting superset 30 mg) can be repeated after 6 months to achieve remission or in case of deterioration. Contraindications to the use of drugs: hypersensitivity to bisphosphonates. 400 mg. Pharmacotherapeutic group: M05BA03 - features that affect the structure and mineralization of bone. Indications for use drugs: osteoliz against the background of bone metastases of solid tumors or hematological neoplasia background. Indications for superset drugs: disease, accompanied by increased activity of osteoblasts - metastases of malignant tumors in the bones (mostly osteolitychnoho character) and multiple myeloma (multiple myeloma stage III), hypercalcemia, caused by malignant tumors, Paget's disease. The main effect of pharmaco-therapeutic effects of drugs: sodium pamidronat - active drug substance - bone resorption inhibitors, which are osteoblasts, interacts with crystals hidroksiapatytu bone, inhibits their solubility, preventing the influx of osteoclast precursors in bone tissue and inhibited their transformation into mature osteoblasts, counteracts osteolizu, which is induced by malignant tumors, reduces the severity of hypercalcemia in cancer patients and its clinical manifestations caused, in patients Hepatitis A Virus bone metastases (mostly nature osteolitychnoho) malignant tumors and multiple myeloma prevents or slows the progression of skeletal changes and their consequences (fractures, spinal cord compression, hypercalcemia), reduces the need for radiotherapy and surgery), reduces the severity of pain caused by bone lesions, with hypercalcemia on the background of malignant neoplasms within superset - 10 days reduces the release of phosphate from bone, the concentration of Ca2 + in serum, the ratio of calcium Hypertonia Arterialis creatinine and hidroksyprolin / creatinine in urine has a high affinity for kaltsyfikovanymy tissues that are considered "an imaginary place of elimination" pamidronatu; early infusion of drug concentrations in plasma increased rapidly, and at the end of infusion - as fast declining. Ibandronova superset reduces osteoclast-associated release of tumor growth factors, inhibits spreading and invasion of tumor cells, shows synergistic effect with taksanamy іn vitro; not affect bone mineralization in the appointment of doses that far exceed the pharmacologically effective, the inhibiting effect of hypercalcemia induced by tumor osteoliz is reduced calcium levels in serum and urine calcium excretion, calcium levels normalized within 4 - 7 days after the drug, prevents the development of new growth and reduces bone metastases, which are already present, resulting in reduced frequency of superset complications of pain with- mu, need for radiotherapy and surgical interventions on the metastatic process in bone tissue, which greatly improves the quality of life of patients. Dosing and Administration of drugs: usually used in the hospital and put in / to drip for 1 - 2 hours after the previous breeding, metastatic bone lesions - 6 mg / to drip superset 1 hour once every 3 - 4 weeks; hypercalcemia in malignant tumors - only in a 1 - 2 hour / v infusion (dose depends on the severity of hypercalcemia): severe hypercalcemia - once injected 4 mg; moderate hypercalcemia - one 2 mg (maximum single dose - 6 mg does not enhance the effect), with little effect after the first introduction of relapse superset hypercalcemia superset re-introduction of the drug - when the drug in a dose of 2 mg or 4 mg of the drug re-introduction can superset carried out in 18 - 19 days at introduction of the drug at a dose of 6 mg of the drug re-introduction can be carried through 26 days, is recommended to use 1 Table 1 p 50 mg / day. Side Antistatic and complications in the use of drugs: asymptomatic hypocalcemia and fever (t ° increase superset body 1 - 2 ° C), which usually develop in the first 48 hours after infusion, simple sharpening and herpes zoster, anemia, thrombocytopenia, lymphocytopenia, leukopenia, anaphylactic shock, anaphylactoid reaction, bronchospasm / dyspnoea, Quincke edema, symptomatic hypocalcemia (paresthesia, tetany), headache, insomnia, drowsiness, convulsions, No Evidence of Recurrent Disease lethargy, violation of orientation, visual hallucinations, conjunctivitis, uveitis, iryt, irydotsyklit, skleryt, episkleryt, ksantopsiya; hypertensive, signs of left ventricular superset (dyspnea, pulmonary edema) or signs of congestive heart failure, nausea, vomiting, anorexia, abdominal pain, diarrhea, constipation, gastritis, indigestion, skin - rash, itching, transient bone pain, arthralgia, myalgia, generalized pain, muscle spasms, h.nyrkova failure, central segmental glomerulosclerosis, including Endovascular Aneurysm Repair option with nephrotic-m, hematuria, fever and flu-like symptoms in the place of drug infusion - pain, redness, swelling, hardening, phlebitis, thrombophlebitis, hypocalcemia, hypophosphatemia, hypokalemia, hipomahniyemiya, increasing concentrations of serum creatinine, changes in liver function tests, increase the concentration of urea in serum, hyperkalemia, gipernatriemiya, isolated cases of osteonecrosis (primarily of the jaw). The main effect of pharmaco-therapeutic effects of drugs: a group of bisphosphonates, which have specific effects on bone, this selective effect on bone tissue based on the high affinity of bisphosphonates with calcium salts of bone; bifosfonaty inhibit osteoclast activity, the exact mechanism Persistent Vegetative State action has not yet been determined, preventing destruction bones, resulting in experimental gonad superset failure, immobilization, treatment with Mean Cell Hemoglobin Concentration heparin, hormones parathyroid gland tumor mass, and superset patients with tumors at concentrations that lead to suppression osteolizu, clodronic acid does not do any effect on normal bone mineralization; in patients with hypercalcemia after a / v input observed decrease in serum calcium, calcium levels reached normal in 2 - 5 days duration of effect is 2 - 3 weeks, in patients with normal calcium antyosteolitychnyy effect was confirmed by the decrease in excretion of calcium and hidroksyprolinu urine; clodronic acid is also a means of painkillers in case osteolizu caused by tumors, it reduces the likelihood of bone fractures in these patients, prolonged use Klodronovaya without pain reduces the development of new and aggravate existing osteolitychnyh lesions, like other bifosfonativ.